Trastuzumab Deruxtecan Archives - Medical Conferences

Practice-changing results of T-DXd in HER2-low breast cancer

Presented By

Prof. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, DESTINY-Breast04

Conference

ASCO 2022

5 August, 2022 12:04

ASCO 2022 Highlights Podcast

Presented By

Dr Robert van den Heuvel, Medicom

Conference

ASCO 2022

21 June, 2022 09:38

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By

Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan

Trial

Phase 2, DESTINY-Gastric01

Conference

ASCO GI 2022

21 March, 2022 11:17

DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO GI 2022

21 March, 2022 10:26

ASCO GI 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2022

8 February, 2022 12:37

Trastuzumab deruxtecan outperforms trastuzumab emtansine

Presented By

Dr Sara Hurvitz, University of California, CA, USA

Trial

Phase 3, DESTINY-Breast03

Conference

SABCS 2021

31 January, 2022 18:02

SABCS 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

SABCS 2021

10 January, 2022 20:59

Trastuzumab deruxtecan triples PFS

Presented By

Dr Javier Cortés, International Breast Cancer Center Barcelona, Spain

Trial

Phase 3, DESTINY-Breast03

Conference

ESMO 2021

19 November, 2021 09:51

Robust anticancer activity of trastuzumab deruxtecan in HER2-mutated NSCLC

Presented By

Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, DESTINY-Lung01

Conference

ESMO 2021

19 November, 2021 09:36

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO 2021

12 August, 2021 21:10

Erika Hamilton, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, TN

Trial

DESTINY-Breast01

Conference

SABCS 2020

13 April, 2021 17:11

HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

Trial

Phase 2, DESTINY-Breast01

Conference

SABCS 2019

13 February, 2020 22:54